Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience

BACKGROUND: The role of immune checkpoint inhibitors (ICIs) in NSCLC patients with EGFR mutations are controversial. In this study, we aim to investigate the therapeutic efficacy of ICIs alone or in combination in patients with EGFR mutated NSCLC in late-line settings, and explore the factors that m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Menglin, Wang, Weiqing, Gao, Xuetian, Wu, Leilei, Jin, Peng, Wu, Hui, Yu, Jinming, Meng, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918499/
https://www.ncbi.nlm.nih.gov/pubmed/35296087
http://dx.doi.org/10.3389/fimmu.2022.832419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918499/
https://www.ncbi.nlm.nih.gov/pubmed/35296087
http://dx.doi.org/10.3389/fimmu.2022.832419

Ejemplares similares